The PAD (Ireland) Study for Patients with Refractory and Relapsed Myeloma: An Update

T Morris; Heather Oakervee; Paul Kettle; Aishleen Brunton; Gary Cook; Martin J. Leahy; Michael R Hamblin; Margaret Murray; H Enright; Mary McCloy; Peter O’Gorman; Kwee Yong; Tanya O’Shea; Rickin Popat; J Cavenagh

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2010

Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program

David S. Siegel, Sundar Jagannath, Roman Hájek, Meletios A Dimopoulos, Sung‐Soo Yoon, Sagar Lonial, Jacob P. Laubach, Thorsten Graef, Dina Pietrangelo, Lisa Lupinacci, David Reiser, Kenneth C. Anderson

Article2009

Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.

David S. Siegel, Sundar Jagannath, Sagar Lonial, Meletios A Dimopoulos, Thorsten Graef, Dina Pietrangelo, Lisa Lupinacci, David Reiser, Syed Rizvi, Kenneth C. Anderson

Chapter in a book2017

Treatment of Relapsed/Refractory Patients with Multiple Myeloma

Jacob P. Laubach, Philippe Moreau, Meletios A Dimopoulos, Paul G. Richardson

Article2022

An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment

Meletios A Dimopoulos, Joseph Mıkhael, Evangelos Terpos, Xavier Leleu, Philippe Moreau, Joan Bladé, Jin Seok Kim, Keith Stockerl‐Goldstein, Paul G. Richardson

Article2022

Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Meletios A Dimopoulos, Paul G. Richardson, Sagar Lonial